What is KeraNetics?
KeraNetics, Inc. is a specialized biotechnology firm focused on creating advanced products to manage radiation dermatitis, a common side effect of radiation therapy. Its flagship product, KeraStat Cream, is an FDA-cleared topical treatment designed to mitigate the symptoms of skin irritation, soreness, and redness experienced by cancer patients undergoing radiotherapy. Founded in collaboration with the Wake Forest Institute for Regenerative Medicine, KeraNetics is committed to enhancing the quality of life for individuals impacted by radiation-induced injuries. The company's strategic focus on this niche medical need positions it as a key player in supportive care for cancer patients.
How much funding has KeraNetics raised?
KeraNetics has raised a total of $5.5M across 3 funding rounds:
Private Equity
$3.4M
Debt
$1.9M
Debt
$150K
Private Equity (2015): $3.4M, investors not publicly disclosed
Debt (2017): $1.9M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
What's next for KeraNetics?
With its recent major strategic investment and a total funding base of $5.5M, KeraNetics is poised for accelerated growth and product expansion. The company's enterprise-level funding context suggests a strategic phase focused on scaling manufacturing, expanding market reach, and potentially advancing its product pipeline. Future developments are likely to center on further clinical validation, broader healthcare provider adoption of KeraStat Cream, and exploring new therapeutic applications for its underlying technology. This capital infusion will be critical in solidifying KeraNetics' market position and advancing its mission to improve patient outcomes in oncology care.
See full KeraNetics company page
